Skip to main content
Top
Published in: Rheumatology International 6/2012

01-06-2012 | Original Article

Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus

Authors: Fan Lian, Dongying Chen, Yu Wang, Yujin Ye, Xiaodong Wang, Zhongping Zhan, Hanshi Xu, Liuqin Liang, Xiuyan Yang

Published in: Rheumatology International | Issue 6/2012

Login to get access

Abstract

Pulmonary arterial hypertension (PAH) is a devastating complication of systemic lupus erythematosus (SLE). We aim to estimate the putative predictors contributing to early identification of PAH, thus improve appropriate medical intervention and a better prognosis. A retrospective case–control study was conducted. Forty-one SLE patients with PAH and 106 SLE patients without PAH were enrolled. Demographic variables, clinical features, and laboratory data were compared between the two groups. Univariate and multivariate logistic regression models were used to examine the predictors contributing to PAH in SLE. Serositis, Raynaud’s phenomenon, high disease activity, anticardiolipin antibodies, and anti-U1RNP were significantly associated with SLE-PAH. Univariate and multivariate analysis showed that Raynaud’s phenomenon, anticardiolipin antibodies, and anti-U1RNP were independent predictors of PAH in SLE. This study highlighted the clinical pattern of SLE-PAH patients, and underlined the leading predictors of PAH development among patients with SLE. Routine echocardiography is recommended in SLE patients with the independent predictors mentioned above.
Literature
1.
go back to reference Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl S):5S–12SPubMedCrossRef Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G et al (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(Suppl S):5S–12SPubMedCrossRef
2.
go back to reference Tanoue LT (2003) Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 24:287–296PubMedCrossRef Tanoue LT (2003) Pulmonary hypertension in the collagen vascular diseases. Semin Respir Crit Care Med 24:287–296PubMedCrossRef
3.
go back to reference Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030PubMedCrossRef Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030PubMedCrossRef
4.
go back to reference Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929PubMed Li EK, Tam LS (1999) Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients. J Rheumatol 26:1923–1929PubMed
5.
go back to reference Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension. A national propective study. Ann Intern Med 107(2):216–223PubMed Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension. A national propective study. Ann Intern Med 107(2):216–223PubMed
6.
go back to reference Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993PubMedCrossRef Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989–993PubMedCrossRef
7.
go back to reference Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thrnton PJ et al (1984) Immunopathologic, clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13(4):349–359PubMedCrossRef Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thrnton PJ et al (1984) Immunopathologic, clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13(4):349–359PubMedCrossRef
8.
go back to reference Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch D, et al (2010) Characterization of connective tissue disease associated pulmonary arteraial hypertension from the reveal registry: identifying system sclerosis as a unique phenotype. Chest 138(6):1383–1394 Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch D, et al (2010) Characterization of connective tissue disease associated pulmonary arteraial hypertension from the reveal registry: identifying system sclerosis as a unique phenotype. Chest 138(6):1383–1394
9.
go back to reference Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O et al (2008) Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 58(2):521–531PubMedCrossRef Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O et al (2008) Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 58(2):521–531PubMedCrossRef
10.
go back to reference Hochberg MC (1997) For the diagnostic and therapeutic criteria committee of the American college of rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) For the diagnostic and therapeutic criteria committee of the American college of rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725PubMedCrossRef
11.
go back to reference Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension, A national prospective study. Ann Intern Med 107:216–233PubMed Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al (1987) Primary pulmonary hypertension, A national prospective study. Ann Intern Med 107:216–233PubMed
12.
go back to reference Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 25(24):2243–2278PubMedCrossRef Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 25(24):2243–2278PubMedCrossRef
13.
go back to reference Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H et al (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):40S–47SPubMedCrossRef Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H et al (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43(Suppl S):40S–47SPubMedCrossRef
14.
go back to reference Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182–189PubMedCrossRef Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M (2006) Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 130:182–189PubMedCrossRef
15.
go back to reference Hachulla E, Gresin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide propective multicenter study. Arthritis Rheum 52(12):3792–3800PubMedCrossRef Hachulla E, Gresin V, Guillevin L, Carpentier P, Diot E, Sibilia J et al (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide propective multicenter study. Arthritis Rheum 52(12):3792–3800PubMedCrossRef
16.
go back to reference Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179(2):151–157PubMedCrossRef Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F et al (2009) Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179(2):151–157PubMedCrossRef
17.
go back to reference Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB (2006) Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25:866–872PubMedCrossRef Chung SM, Lee CK, Lee EY, Yoo B, Lee SD, Moon HB (2006) Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 25:866–872PubMedCrossRef
18.
go back to reference Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287PubMed Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N (2002) Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 29:282–287PubMed
19.
go back to reference Guillevin L (2009) Vasculopathy and pulmonary arterial hypertension. Rheumatology 48(Suppl 3):iii54–iii57PubMedCrossRef Guillevin L (2009) Vasculopathy and pulmonary arterial hypertension. Rheumatology 48(Suppl 3):iii54–iii57PubMedCrossRef
20.
go back to reference Wigley FM (1996) Raynaud’s phenomenon and other features of scleroderma, including pulmonary hypertension. Curr Opin Rheumatol 8:561–568PubMedCrossRef Wigley FM (1996) Raynaud’s phenomenon and other features of scleroderma, including pulmonary hypertension. Curr Opin Rheumatol 8:561–568PubMedCrossRef
21.
go back to reference Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31(2):183–189 Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al (2011) Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 31(2):183–189
22.
go back to reference Kasparian A, Floros A, Gialafos E, Kanakis M, Tassiopoulos S, Kafasi N et al (2007) Raynaud’s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16(7):505–508PubMedCrossRef Kasparian A, Floros A, Gialafos E, Kanakis M, Tassiopoulos S, Kafasi N et al (2007) Raynaud’s phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 16(7):505–508PubMedCrossRef
23.
go back to reference Levien TL (2010) Advances in the treatment of Raynaud’s phenomenon. Vasc Health Risk Manag 24(6):167–177CrossRef Levien TL (2010) Advances in the treatment of Raynaud’s phenomenon. Vasc Health Risk Manag 24(6):167–177CrossRef
24.
go back to reference Haas C (2004) Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 188(6):985–997PubMed Haas C (2004) Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 188(6):985–997PubMed
25.
go back to reference Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23(2):199–204PubMed Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23(2):199–204PubMed
26.
go back to reference Asherson RA, Cervera R (2007) Pulmonary hypertension, antiphospholipid antibodies and syndromes. Clin Rev Allergy Immunol 32(2):153–158PubMedCrossRef Asherson RA, Cervera R (2007) Pulmonary hypertension, antiphospholipid antibodies and syndromes. Clin Rev Allergy Immunol 32(2):153–158PubMedCrossRef
27.
go back to reference Grunig E, Ehlken N, Ch Nagel (2008) Anticoagulation in pulmonary arterial hypertension. Hamostaseologie 8(4):225–230 Grunig E, Ehlken N, Ch Nagel (2008) Anticoagulation in pulmonary arterial hypertension. Hamostaseologie 8(4):225–230
28.
go back to reference Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M et al (1999) Immunological analysis of pulmonary hypertension in connective tissue disease. J Rheumatol 26(11):2357–2362PubMed Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M et al (1999) Immunological analysis of pulmonary hypertension in connective tissue disease. J Rheumatol 26(11):2357–2362PubMed
29.
go back to reference Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44(2):376–383PubMedCrossRef Gussin HA, Ignat GP, Varga J, Teodorescu M (2001) Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 44(2):376–383PubMedCrossRef
30.
go back to reference McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al (2004) American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):78S–92SPubMedCrossRef McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T et al (2004) American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):78S–92SPubMedCrossRef
31.
go back to reference Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243PubMedCrossRef Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM (1997) Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 36:239–243PubMedCrossRef
32.
go back to reference Vachiery JL, Brimioulle S, Crasset V, Naeije R (1998) False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur Respir J 12:1476–1478PubMedCrossRef Vachiery JL, Brimioulle S, Crasset V, Naeije R (1998) False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur Respir J 12:1476–1478PubMedCrossRef
Metadata
Title
Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus
Authors
Fan Lian
Dongying Chen
Yu Wang
Yujin Ye
Xiaodong Wang
Zhongping Zhan
Hanshi Xu
Liuqin Liang
Xiuyan Yang
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-1880-4

Other articles of this Issue 6/2012

Rheumatology International 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.